Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Functional Technologies Corp FEBTF



GREY:FEBTF - Post by User

Post by skyhi0on Dec 14, 2006 12:51pm
146 Views
Post# 11867701

About....

About....4 months and 24 days until the pre-feasability study is out. Most importantly such a study should likely incorporate volume and time line calculations giving an indication of future sales. As H. Louie says " critical path to commercialization ". First Venture Technologies Corp. (TSX VENTURE:FEB) announced today that it has entered into an agreement with Canbiotech Consultants Inc., of Selkirk, Ontario, to conduct a pre-feasibility study for the establishment of a commercial active dry-yeast manufacturing facility in Canada. The study will take about five months to complete and will produce a preliminary design for a cost-effective commercial manufacturing facility for the production and processing of the company's proprietary yeast in active dry form. The study will also incorporate a comprehensive analysis of the best prospective geographical locations for the manufacturing operations. The facility is to be fully compliant with Canadian regulatory guidelines that address the yeast manufacturing industry. "We are pleased to be entering into this important stage of corporate development," said Howard Louie, President and CEO. "The ability to secure a long term commercial supply of multiple strains of our proprietary yeast is an important component of our next stage of growth. This is an integral part of our commercial strategy and is along the critical path to commercialization of our proprietary yeast strains that have been shown, in over one hundred lab fermentation trials, to be highly efficacious in reducing the presence of a known carcinogen from fermented foods and beverages."
Bullboard Posts